Corporate Mission

Xenomics, Inc. is the developer of next-generation molecular diagnostics products that address important health problems worldwide.

Our mission is to apply our proprietary transrenal DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics that replace outdated blood, sputum, and tissue testing technologies many of which are not sufficiently sensitive and specific, and are often hazardous, and difficult to automate.

The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets including infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, human forensics, and biodefense.

Xenomics has made continuing progress in its clinical studies in infectious disease testing, particularly in the field of TB detection and therapeutic monitoring, HIV proviral DNA detection, and detection of early cancer genetic markers.